BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 23290326)

  • 1. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics.
    Szegedi A; Verweij P; van Duijnhoven W; Mackle M; Cazorla P; Fennema H
    J Clin Psychiatry; 2012 Dec; 73(12):1533-40. PubMed ID: 23290326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia.
    Buchanan RW; Panagides J; Zhao J; Phiri P; den Hollander W; Ha X; Kouassi A; Alphs L; Schooler N; Szegedi A; Cazorla P
    J Clin Psychopharmacol; 2012 Feb; 32(1):36-45. PubMed ID: 22198451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asenapine for the treatment of adults with an acute exacerbation of schizophrenia: results from a randomized, double-blind, fixed-dose, placebo-controlled trial with olanzapine as an active control.
    Landbloom R; Mackle M; Wu X; Kelly L; Snow-Adami L; McIntyre RS; Mathews M; Hundt C
    CNS Spectr; 2017 Aug; 22(4):333-341. PubMed ID: 27821210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy from an 8 Week Double-Blind Trial and a 26 Week Open-Label Extension of Asenapine in Adolescents with Schizophrenia.
    Findling RL; Landbloom RP; Mackle M; Pallozzi W; Braat S; Hundt C; Wamboldt MZ; Mathews M
    J Child Adolesc Psychopharmacol; 2015 Jun; 25(5):384-96. PubMed ID: 26091193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    Bipolar Disord; 2009 Nov; 11(7):673-86. PubMed ID: 19839993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Dec; 63(12):1762-84. PubMed ID: 19840150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
    Demyttenaere K; Detraux J; Racagni G; Vansteelandt K
    CNS Drugs; 2019 Jun; 33(6):549-566. PubMed ID: 31065941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
    McIntyre RS; Cohen M; Zhao J; Alphs L; Macek TA; Panagides J
    J Affect Disord; 2010 Apr; 122(1-2):27-38. PubMed ID: 20096936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia.
    Kane JM; Cohen M; Zhao J; Alphs L; Panagides J
    J Clin Psychopharmacol; 2010 Apr; 30(2):106-15. PubMed ID: 20520283
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study.
    Kinoshita T; Bai YM; Kim JH; Miyake M; Oshima N
    Psychopharmacology (Berl); 2016 Jul; 233(14):2663-74. PubMed ID: 27271087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asenapine: a clinical review of a second-generation antipsychotic.
    Stoner SC; Pace HA
    Clin Ther; 2012 May; 34(5):1023-40. PubMed ID: 22494521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
    Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
    J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.
    Potkin SG; Cohen M; Panagides J
    J Clin Psychiatry; 2007 Oct; 68(10):1492-500. PubMed ID: 17960962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic-pharmacodynamic modelling of antipsychotic drugs in patients with schizophrenia: part II: the use of subscales of the PANSS score.
    Pilla Reddy V; Kozielska M; Suleiman AA; Johnson M; Vermeulen A; Liu J; de Greef R; Groothuis GM; Danhof M; Proost JH
    Schizophr Res; 2013 May; 146(1-3):153-61. PubMed ID: 23473811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review and Network Meta-Analysis to Assess the Relative Efficacy of Antipsychotics for the Treatment of Positive and Negative Symptoms in Early-Onset Schizophrenia.
    Harvey RC; James AC; Shields GE
    CNS Drugs; 2016 Jan; 30(1):27-39. PubMed ID: 26801655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation.
    Pratts M; Citrome L; Grant W; Leso L; Opler LA
    Acta Psychiatr Scand; 2014 Jul; 130(1):61-8. PubMed ID: 24606117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program.
    Leucht S; Zhao J
    J Psychopharmacol; 2014 Apr; 28(4):387-94. PubMed ID: 24429222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Tolerability of Asenapine Compared with Olanzapine in Borderline Personality Disorder: An Open-Label Randomized Controlled Trial.
    Bozzatello P; Rocca P; Uscinska M; Bellino S
    CNS Drugs; 2017 Sep; 31(9):809-819. PubMed ID: 28741044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.